NASDAQ
Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)...
MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule,...
Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Q...
MARIETTA, Ga. , Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market cl...
Next-Generation, Lyophilized Human Placental Allograft Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Next-Generation, Lyophilized Human Placental Allograft Further Expands Company's Broad Portfolio of Advanced Woun...
No price data available for this timeframe.